CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corporation (CAMP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
camp · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CAMP4 Therapeutics Corporation (CAMP) measures how much investors pay for each dollar of the company's trailing earnings. CAMP's current PE ratio of N/A is calculated by dividing its stock price of $4.09 by its TTM earnings per share of -$1.49.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 7 fiscal years · Front-end computedMinQ1 · 25%23.1x
MedianQ3 · 75%56.8x
Max
At N/A, CAMP's current P/E is lower than in 0% of its annual fiscal year readings over the past 7 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CAMP4 Therapeutics CorporationYou CAMP | $87M | N/A | — | -$1.49 |
 Acrivon Therapeutics, Inc. Common Stock ACRV | $44M | N/A | — | -$2.02 |
 ALX Oncology Holdings Inc. ALXO | $211M | N/A | — | -$1.90 |
 aTyr Pharma, Inc. ATYR | $43M | N/A | — | -$0.80 |
 Biomea Fusion, Inc. BMEA | $68M | N/A | — | -$1.18 |
 MindWalk Holdings Corp. HYFT | $75M | N/A | — | -$0.91 |
 PMV Pharmaceuticals, Inc. PMVP | $58M | N/A | — | -$1.48 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.65 | — | |
2024-12-31 FY2024 | — | $-2.66 | — | |
2023-12-31 FY2023 | — | $-4.07 | — | |
2023-02-28 FY2023 | — | $-1.22 | — | |
2022-02-28 FY2022 | — | $-0.88 | — | |
2021-02-28 FY2021 | — | $-0.62 | — | |
2020-02-29 FY2020 | — | $-2.35 | — | |
2019-02-28 FY2019 | 20.15x | $0.53 | -11.4% | |
2018-02-28 FY2018 | 22.74x | $0.47 | — | |
2017-02-28 FY2017 | — | $-0.20 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CAMP4 Therapeutics Corporation (CAMP) measures how much investors pay for each dollar of the company's trailing earnings. CAMP's current PE ratio of N/A is calculated by dividing its stock price of $4.09 by its TTM earnings per share of -$1.49.
Frequently asked questions
CAMP pe ratio · 6 questionsCAMP's current PE ratio is N/A as of 2026-06-09, based on a stock price of $4.09 and TTM EPS of -$1.49. Data sourced from Financial Modeling Prep via CAMP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CAMP4 Therapeutics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09